Back to top
more

Basilea Pharmaceutica (BPMUF)

(Delayed Data from OTC)

$48.15 USD

48.15
NA

0.00 (0.00%)

Updated May 20, 2024 01:51 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BPMUF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Basilea Pharmaceutica AG [BPMUF]

Reports for Purchase

Showing records 21 - 40 ( 73 total )

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 21

09/29/2023

Company Report

Pages: 2

Zevtera (ceftobiprole) clinical data published

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 22

08/17/2023

Company Report

Pages: 7

A strong start to FY23 across the board

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 12.50

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 23

08/16/2023

Company Report

Pages: 5

Mid-Year Report Showcases Impressive Operating Progress; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 24

08/11/2023

Company Report

Pages: 5

Cresemba Supplemental New Drug Application Accepted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 25

08/07/2023

Company Report

Pages: 2

Zevtera back on track: NDA submitted to the FDA

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 26

08/04/2023

Company Report

Pages: 5

Ceftobiprole New Drug Application Submitted to FDA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 27

07/24/2023

Company Report

Pages: 5

Ceftobiprole Regulatory Submission Imminent; Raising PT to CHF90

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 28

06/09/2023

Company Report

Pages: 2

Prompt receipt of milestone payments for Cresemba

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 29

04/19/2023

Company Report

Pages: 2

Zevtera NDA submission pushed to Q323

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 30

03/23/2023

Company Report

Pages: 2

Cresemba expansion continues with Japan launch

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 31

02/17/2023

Company Report

Pages: 8

Profitability sooner than expected

Provider: Edison Investment Research Limited

Analyst: PRAKASH J

Price: 12.50

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 32

01/25/2023

Company Report

Pages: 2

Strong execution resulting in operating profitability

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 33

01/12/2023

Company Report

Pages: 2

Revenue upside surprise for 2022

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 34

01/10/2023

Company Report

Pages: 2

Cresemba milestone payment triggered

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 35

01/04/2023

Company Report

Pages: 2

Third leg of strategy executed with debt repayment

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 36

12/21/2022

Company Report

Pages: 3

Oncology milestone payment triggered

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 37

11/02/2022

Company Report

Pages: 2

Third oncology asset sale announced, as planned

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 38

10/26/2022

Company Report

Pages: 5

Ceftobiprole ERADICATE Trial Data Presented; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 39

10/25/2022

Company Report

Pages: 2

New supportive data from ERADICATE

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 5.00

Research Provided by a Third Party

Company: Basilea Pharmaceutica AG

Industry: Medical - Biomedical and Genetics

Record: 40

10/03/2022

Company Report

Pages: 5

BAL0891 Licensing Deal Consummated; Raising PT to CHF87

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party